Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients with Advanced Non-Adipocytic Soft Tissue Sarcomas By Ogkologos - April 28, 2025 841 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EREMISS study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Resilience Isn’t About Bouncing Back March 8, 2021 FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or... December 2, 2021 Efficacy and Safety of Adjuvant Nivolumab for High-Risk Muscle-Invasive Urothelial Carcinoma... June 7, 2021 Cancer in My Community: Caring for Children With Cancer in Armenia July 2, 2020 Load more HOT NEWS Navigating Cancer Survivorship as a Transgender or Non-Binary Person Mohs Surgery for Skin Cancer: What to Know and What to... EMA Recommends Extension of Indications for Darolutamide Texting May Help Reduce Disparities in Colorectal Cancer Screening
